All In Biotech

Drug Trial Radar · NCT00548405

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy

Last checked: Nov 20, 2026Latest source record: Apr 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 840 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

840

Actual

Start

Oct 2007

Primary completion

Sep 2011

Study completion Sep 2011

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
Collaborators
Bayer
First posted
Oct 24, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon beta-1a (Rebif®). The study enrolled participants who had received an adequate trial of disease-modifying therapies but experienced at least 1 relapse during prior treatment, and who met a minimum severity of disease as measured by magnetic resonance imaging (MRI). Participants had monthly laboratory tests and comprehensive testing every 3 months.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

  • Alemtuzumab 12 mgBiological

    Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.

  • Alemtuzumab 24 mgBiological

    Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.

  • Interferon beta-1aBiological

    Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Sustained Accumulation of Disability (SAD)Time frame: Up to 2 years
  2. Annualized Relapse RateTime frame: Up to 2 years

Locations

191 sites in 23 countries. Site status is shown where the registry gives one.

  • North Central Neurology Associates, P.C.

    Cullman, Alabama

  • Barrow Neurological Institute, St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Hope Research Institute

    Phoenix, Arizona

  • Mayo Clinic Arizona, Department of Neurology

    Scottsdale, Arizona

  • Northwest NeuroSpecialists, PLLC

    Tucson, Arizona

  • East Bay Physicians Medical Group/Sutter East Bay Medical Foundation

    Berkeley, California

  • Neurology Center of North Orange County

    La Habra, California

  • Department of Neurology, Keck School of Medicine, University of Southern California

    Los Angeles, California

  • Neuro-Therapeutics Inc.

    Pasadena, California

  • Neuro-Therapeutics, Inc

    Pasadena, California

  • University of California, Davis Medical Center

    Sacramento, California

  • Stanford University School of Medicine

    Stanford, California

  • University of Colorado Hospital, Anschutz Outpatient Pavilioin

    Aurora, Colorado

  • Neurological Consultants

    Denver, Colorado

  • Advanced Neurosciences Research

    Fort Collins, Colorado

  • Yale University

    New Haven, Connecticut

  • George Washington University Medical Faculty Associates

    Washington D.C., District of Columbia

  • University of Florida Neuroscience Institute

    Jacksonville, Florida

  • Neurology Associates, P.A.

    Maitland, Florida

  • Neurological Associates

    Pompano Beach, Florida

  • Negroski, Stein, Sutherland and Hanes Neurology

    Sarasota, Florida

  • Axiom Clinical Research of Florida

    Tampa, Florida

  • University of South Florida, Department of Neurology

    Tampa, Florida

  • Emory University, Department of Neurology

    Atlanta, Georgia

  • Shepherd Center, Inc.

    Atlanta, Georgia

  • Idaho Falls Multiple Sclerosis Center, PLLC

    Idaho Falls, Idaho

  • University of Chicago Medical Center, Department of Neurology

    Chicago, Illinois

  • Consultants in Neurology, Ltd

    Northbrook, Illinois

  • Fort Wayne Neurological Center

    Fort Wayne, Indiana

  • Indiana University School of Medicine, Department of Neurology

    Indianapolis, Indiana

  • Josephson Wallack Munshower Neurology P.C.

    Indianapolis, Indiana

  • Iowa Health Physicians

    Des Moines, Iowa

  • Ruan Neurology Clinic and Research Center

    Des Moines, Iowa

  • University of Kansas Medical Center, Department of Neurology

    Kansas City, Kansas

  • MidAmerica Neuroscience Institute

    Lenexa, Kansas

  • Associates in Neurology, PSC

    Lexington, Kentucky

  • University of Louisville Research Foundation

    Louisville, Kentucky

  • Louisiana State University Health Sciences Center

    Shreveport, Louisiana

  • Caritas St. Elizabeth's Medical Center

    Boston, Massachusetts

  • Partners Multiple Sclerosis Center/Brigham and Women's Hospital

    Boston, Massachusetts

Showing 40 of 191 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.